Trials / Completed
CompletedNCT01039818
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Hospital de Clinicas de Porto Alegre · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether higher doses of radioiodine increase treatment efficacy in severe Graves' disease.
Detailed description
Graves' disease (GD) is the most frequent cause of hyperthyroidism, affecting mainly women aged 40-60 years. Radioiodine (¹³¹I), introduced in 1941, has become a cornerstone in the treatment of GD hyperthyroidism. Because of its safety, low costs and rapid effect, it is considered a first line therapy in the United States. However, treatment failure occurs in about 15-25% of patients treated with radioiodine. Patients not cured with the first dose of radioiodine usually present severe hyperthyroidism, characterized by large goiter, high 24-hour radioiodine uptake (24h-RAIU) and very high levels of thyroid hormones. We have previously shown that large goiter (≥48ml) is an independent predictor of treatment failure. In these patients, the therapeutic failure was 40.0% while in patients with smaller goiter was only 6.5% (P=0.005; unpublished). It is generally accepted that higher doses of radioiodine improves cure rates. Indeed, a recent meta-analysis found a correlation between radioiodine dose and therapeutic success in GD patients. To our knowledge, there are no published studies evaluating cure rates with different radioiodine doses in severe GD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radioiodine | A unique dose of 200µCi of ¹³¹I/ml/24-RAIU |
| RADIATION | Radioiodine | A unique dose of 250µCi of ¹³¹I/ml/24-RAIU |
Timeline
- Start date
- 1997-02-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2009-12-25
- Last updated
- 2012-09-06
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01039818. Inclusion in this directory is not an endorsement.